Concepedia

Matthew D. Troyer

MD

Statistics

Publications

35

Citations

4.7K

H-Index

24

Active since

1992

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Denali Therapeutics (United States)

University of California, San Francisco

Centre for Human Drug Research

Leiden University Medical Center

Matthew D. Troyer is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicine, and neuropharmacology.

ORCID

Publications per year

1992–2023

35

Publications

35

The Expression of Vesicular Glutamate Transporters Defines Two Classes of Excitatory Synapse

Robert T. Fremeau, Matthew D. Troyer, Ingrid Pahner et al. · Neuron · 2001 · 1.3K citations · Full text

, , +14

Lipid Rafts Mediate the Synaptic Localization of α-Synuclein

Doris L. Fortin, Matthew D. Troyer, Ken Nakamura et al. · Journal of Neuroscience · 2004 · 520 citations · Full text

, , +17

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy, Andrew W. Stamford, Xia Chen et al. · Science Translational Medicine · 2016 · 417 citations

, , +17

α-Synuclein Overexpression in PC12 and Chromaffin Cells Impairs Catecholamine Release by Interfering with a Late Step in Exocytosis

Kristin E. Larsen, Yvonne Schmitz, Matthew D. Troyer et al. · Journal of Neuroscience · 2006 · 412 citations · Full text

, , +17

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease

Daniel Weintraub, Tanya Simuni, Chelsea Caspell‐Garcia et al. · Movement Disorders · 2015 · 307 citations · Full text

, , +17

1–5 of 35